Dec 9, 2017
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT03269136 MAGNETISMM-1 RRMM NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma To...
497
Dec 9, 2016
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, & Citarinostat +/- Lenalidomide for Smoldering MM
NCT02886065: Phase 1 - PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM A Study of PVX-410, a Cancer...
196
Dec 11, 2010
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NDMM - DFCI 10-106 DETERMINATION Trial Delayed vs Early Transplant with Revlimid Maintenance and Anti-Myeloma Triple Therapy DFCI 10-106...
1,112